StatOrigin open statistical archive
Industries Indicators Regions Rankings Compare Sources

GSK

28 data points extracted from 4 publications by this organisation.

Cite & reuse Official site Get this data as JSON
Data points
28
Documents
4
Indicators
28
Regions
3
Publisher type
Company

Bibliography

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Published Retrieved Link Data points
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK Licence: See source Press release — 17 Sep 2026 Reachable 4
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026 Licence: See source Press release — 17 Sep 2026 Reachable 20
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data Licence: See source Press release — 15 Sep 2026 Reachable 3
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences Licence: See source Press release — 15 Sep 2026 Reachable 1

Every figure

Data points

Every figure taken from this organisation, grouped by indicator.

28 data points across 28 indicators.
IndicatorRegionPeriodValueTypeFull record
Biopharma, biotech and AI companies countUnited Kingdomas of 28 Jul 2026470actual →
Clinical development drug pipeline assets countGlobalas of 28 Jul 202662actual →
Core operating profit growth (quarterly)GlobalQ2 20267%actual →
General medicines sales growth (quarterly)GlobalQ2 2026-9%actual →
General medicines sales revenue (quarterly)GlobalQ2 20262.3 billion GBPactual →
HIV medicines sales growth (quarterly)GlobalQ2 202610%actual →
HIV medicines sales revenue (quarterly)GlobalQ2 20262.1 billion GBPactual →
Influenza casesGlobal20261 billionestimate →
Influenza deathsGlobal2026650,000estimate →
Life sciences employmentUnited Kingdomas of 28 Jul 202622,000actual →
Long-term annual sales outlookGlobal203140 billion GBPforecast →
Oncology sales growth (quarterly)GlobalQ2 202617%actual →
Oncology sales revenue (quarterly)GlobalQ2 20260.6 billion GBPactual →
Operating profit growth (quarterly)GlobalQ2 2026-75%actual →
Pharmaceutical and life sciences R&D facility investmentUnited Kingdomas of 28 Jul 2026400 million GBPestimate →
Pharmaceutical and life sciences R&D facility investment (annual)United Kingdom2026–2029400 million GBPforecast →
Pharmaceutical sales revenueGlobalQ2 20268.4 billion GBPactual →
Phase III clinical trial starts (annual)Global202620forecast →
Respiratory immunology and inflammation sales growth (quarterly)GlobalQ2 202619%actual →
Respiratory immunology and inflammation sales revenue (quarterly)GlobalQ2 20261.1 billion GBPactual →
Sales growth at actual exchange rates (quarterly)GlobalQ2 20265%actual →
Sales growth at constant exchange rates (quarterly)GlobalQ2 20265%actual →
Severe influenza casesGlobal20265 millionestimate →
Specialty medicines sales growth (quarterly)GlobalQ2 202614%actual →
Specialty medicines sales revenue (quarterly)GlobalQ2 20263.8 billion GBPactual →
T-cell engager market size for multiple myelomaUnited States203210 billion USDforecast →
Vaccines sales growth (quarterly)GlobalQ2 20268%actual →
Vaccines sales revenue (quarterly)GlobalQ2 20262.3 billion GBPactual →

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. Credit GSK as the original publisher; each record page carries its own citation.

GSK. Retrieved from StatOrigin: https://statorigin.org/sources/gsk

This organisation as JSON

Keep exploring

Related

Industries using this source

Go further

Last verified 17 September 2026. Link status is rechecked weekly.